Clinical trials: Olanzapine
Schizophrenia
Exploratory Cognition Study of Sertindole in Patients With Schizophrenia
The purpose of this exploratory study is to evaluate the effects of sertindole and olanzapine on neurocognitive functioning in patients with schizophrenia.
- Trial name
- NCT00759421
- Testing
- Sertindole, Olanzapine
- Where
- Taiwan
- Volunteers
- 96 people
- Sponsor
- H. Lundbeck A/S
Bipolar Disorder
Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder
The goals of this study are: A. To determine whether olanzapine can help patients with bipolar disorder who currently have mild to moderate mania. B.
- Trial name
- NCT00094549
- Testing
- olanzapine, divalproex sodium
- Where
- 42 sites in United States, Lithuania and 3 more
- Volunteers
- 500 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizoaffective Disorders
Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine
The goal of this study is to answer the following questions: Whether treatment with amantadine, metformin or zonisamide can prevent or reverse the weight gain that is associated with olanzapine Whether taking amantadine…
- Trial name
- NCT00401973
- Testing
- olanzapine, amantadine, metformin
- Where
- 15 sites in United States, Brazil and 5 more
- Volunteers
- 199 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital
The study will assess the use of paliperidone palmitate compared with oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 12 months, in patients diagnosed with schizophrenia who were…
- Trial name
- NCT01193166
- Testing
- paliperidone palmitate, risperidone, olanzapine
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Schizophrenia
Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia
The purpose of this study is to determine whether a low dose and a high dose of the study drug SCA-136 are effective and safe in the treatment of schizophrenia requiring hospitalization.
- Trial name
- NCT00265551
- Testing
- SCA-136 (200 mg), SCA-136 (400 mg), olanzapine (15 mg)
- Where
- 35 sites in United States
- Volunteers
- 300 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Bipolar I Disorder, Schizophrenia
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
To evaluate the long-term safety and tolerability of OLZ/SAM in pediatric subjects with schizophrenia or Bipolar I disorder
- Trial name
- NCT04987229
- Testing
- OLZ/SAM
- Where
- 35 sites in United States, Argentina and 3 more
- Volunteers
- 236 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia
The purpose of this study is to evaluate the effectiveness and safety of Extended Release Osmotic Controlled-Release Oral Delivery System (OROS) Paliperidone compared to placebo in patients with Schizophrenia.
- Trial name
- NCT00396565
- Testing
- ER OROS paliperidone, Olanzapine
- Where
- 56 sites in Japan
- Volunteers
- 394 people
- Sponsor
- Janssen Pharmaceutical K.K.
Treatment-resistant Schizophrenia
Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia
This study evaluates the efficacy of 10 mg/day Lu AF35700 on symptoms of schizophrenia in patients with early-in-disease (ED) or late-in-disease (LD) treatment-resistant schizophrenia (TRS)
- Trial name
- Anew (NCT03230864)
- Testing
- Lu AF35700, Risperidone, Olanzapine
- Where
- 41 sites in United States, Bulgaria and 3 more
- Volunteers
- 119 people
- Sponsor
- H. Lundbeck A/S
Healthy
Food Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg
The objective of this study was to investigate the bioequivalence of Mylan olanzapine 5 mg tablets to Eli Lilly's Zyprexa® 5 mg tablets following a single, oral 5 mg (1 x 5 mg) dose administered under fed conditions.
- Trial name
- NCT00647777
- Testing
- Olanzapine Tablets 5 mg, Zyprexa® Tablets 5 mg
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Schizophrenia, Bipolar I Disorder
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
- Trial name
- NCT05303064
- Testing
- OLZ/SAM, Olanzapine
- Where
- 47 sites in United States, Argentina and 3 more
- Volunteers
- 220 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
The purpose of this study is to determine whether LY2140023, when added to standard-of-care antipsychotic treatment, will improve negative symptoms.
- Trial name
- NCT01052103
- Testing
- LY2140023, Standard of Care
- Where
- 9 sites in United States, Israel and 2 more
- Volunteers
- 167 people
- Sponsor
- Denovo Biopharma LLC
Psychoses
DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics
The purpose of this study is to assess patients treated with the antipsychotics aripiprazole (Abilify®), olanzapine (Zyprexa®), quetiapine (Seroquel®), risperidone (Risperdal®), or ziprasidone (Geodon®) and to identify genetic…
- Trial name
- DIMS (NCT00752960)
- Where
- 2 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Genomas, Inc
Schizophrenia, Psychotic Disorders
The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity.
- Conditions
- Schizophrenia, Psychotic Disorders, Bipolar Disorder
- Trial name
- NCT00044187
- Testing
- Sibutramine
- Where
- 16 sites in United States
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Agitation in Adolescents and Young Adults With ASD
INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD
This is a Phase 2a, proof-of concept, 2-way, 2-period crossover, double-blind study to evaluate the safety and efficacy of INP105 as an acute treatment versus placebo in adolescents and young adults with autism spectrum disorder…
- Trial name
- CALM 201 (NCT05163717)
- Testing
- INP105
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Impel Pharmaceuticals
Schizophrenia, Schizoaffective Disorder
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)
The primary features of schizophrenia and schizoaffective disorder are positive (inability to think clearly and distinguish reality from fantasy) and negative symptoms (reduction or absence of normal behavior or emotions).
- Trial name
- ACTAMESA (NCT00212771)
- Testing
- asenapine, olanzapine
- Volunteers
- 440 people
- Sponsor
- Organon and Co
Schizophrenia, Psychotic Disorders
Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study
This study intends to compare novel antipsychotics ziprasidone and olanzapine, to confirm the findings of an open study -where stable patients receiving olanzapine switched to ziprasidone- which showed maintenance of clinical…
- Trial name
- NCT00145444
- Testing
- olanzapine, ziprasidone
- Where
- 7 sites in Belgium, Netherlands
- Volunteers
- 100 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
The study will assess the use of paliperidone palmitate compared with oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 15 months, in patients diagnosed with schizophrenia who have been…
- Trial name
- NCT01157351
- Testing
- paliperidone, risperidone, haloperidole
- Where
- 56 sites in United States, Puerto Rico
- Volunteers
- 450 people
- Sponsor
- Janssen Scientific Affairs, LLC
Schizophrenia, Psychotic Disorders
A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
The purpose of the study is to compare effectiveness of paliperidone palmitate (PP: paliperidone palmitate once-monthly and 3-month injections) versus oral antipsychotic (OAP [that is oral paliperidone extended release {ER}, oral…
- Trial name
- DREaM (NCT02431702)
- Testing
- Aripiprazole, Haloperidol, Olanzapine
- Where
- 38 sites in United States, Brazil and 1 more
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- Janssen Scientific Affairs, LLC
Schizophrenia
Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia
The primary objective of the double-blind phase of this study is to evaluate the efficacy and safety of 3 fixed dosages of paliperidone ER (3, 9, and 15 mg/day) compared with placebo in adult patients with schizophrenia
- Trial name
- NCT00083668
- Testing
- Paliperidone ER
- Volunteers
- 619 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Bipolar Disorder
Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder
The purpose of this study is to confirm the efficacy of olanzapine in the treatment of manic or mixed symptoms associated with bipolar I disorder.
- Trial name
- NCT00129220
- Testing
- olanzapine, haloperidol
- Where
- 16 sites in Japan
- Volunteers
- 224 people
- Sponsor
- Eli Lilly and Company